Bogle Investment Management LP Has Lowered Vanda Pharmaceuticals Com (VNDA) Stake; Weitz Investment Management Has Trimmed Liberty Interactive (QVCA) Position

August 12, 2018 - By Carolyn Hewitt

Liberty Interactive Corporation (NASDAQ:QVCA) Logo

Weitz Investment Management Inc decreased Liberty Interactive Corp (QVCA) stake by 31.77% reported in 2018Q1 SEC filing. Weitz Investment Management Inc sold 819,330 shares as Liberty Interactive Corp (QVCA)’s stock 0.00%. The Weitz Investment Management Inc holds 1.76M shares with $44.28M value, down from 2.58 million last quarter. Liberty Interactive Corp now has $ valuation. The stock increased 2.76% or $0.75 during the last trading session, reaching $27.93. About 2.34 million shares traded or Infinity% up from the average. Liberty Interactive Corporation (NASDAQ:QVCA) has 0.00% since August 12, 2017 and is . It has underperformed by 12.57% the S&P500. Some Historical QVCA News: 07/03/2018 – LIBERTY EXPEDIA HOLDINGS – ON MARCH 6, ENTERED AGREEMENT TO EXTEND PROXY ARRANGEMENT TERMINATION DATE WITH LIBERTY INTERACTIVE, JOHN MALONE, OTHERS; 14/03/2018 – S&PGR Downgrades Liberty Interactive’s Sr Unsecured Notes; 08/03/2018 – Liberty Interactive and GCI Liberty Announce Completion of Auto Conversion, Reattribution and Expected Closing of Transactions; 05/03/2018 LIBERTY INTERACTIVE CORP QVCA.O : UBS RAISES TARGET PRICE TO $33 FROM $30

Bogle Investment Management Lp decreased Vanda Pharmaceuticals Com (VNDA) stake by 28.48% reported in 2018Q1 SEC filing. Bogle Investment Management Lp sold 92,266 shares as Vanda Pharmaceuticals Com (VNDA)’s stock declined 10.16%. The Bogle Investment Management Lp holds 231,731 shares with $3.91 million value, down from 323,997 last quarter. Vanda Pharmaceuticals Com now has $1.13B valuation. The stock increased 0.46% or $0.1 during the last trading session, reaching $21.65. About 487,636 shares traded or 15.96% up from the average. Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) has risen 22.78% since August 12, 2017 and is uptrending. It has outperformed by 10.21% the S&P500. Some Historical VNDA News: 15/05/2018 – Cormorant Asset Management Buys 1.8% Position in Vanda Pharma; 13/04/2018 – CAFC: VANDA PHARMACEUTICALS INC. v. WEST-WARD PHARMACEUTICALS [OPINION] – Appeal #16-2707 – 2018-04-13; 02/05/2018 – Vanda Pharmaceuticals: Reiterates Prior 2018 Fincl Guidance; 02/05/2018 – Vanda Pharmaceuticals 1Q EPS 6c; 02/05/2018 – Vanda Pharmaceuticals 1Q Rev $43.6M; 15/03/2018 – Vanda Pharmaceuticals Inc. Prices Public Offering of Common Stkat $17/Share; 23/05/2018 – VANDA SAYS HETLIOZ ) EFFECTIVE IN TREATING JET LAG DURING; 14/03/2018 – Vanda Pharmaceuticals Inc. Proposes Public Offering of Common Stk; 13/04/2018 – VANDA PHARMACEUTICALS INC – ‘610 PATENT IS SET TO EXPIRE NOVEMBER 2, 2027; 13/04/2018 – Vanda Wins Appeal Case on Fanapt

Since February 28, 2018, it had 0 insider buys, and 4 sales for $1.53 million activity. 3,660 shares were sold by Gulino Richard L., worth $68,473. Shares for $159,712 were sold by Kelly James Patrick on Wednesday, February 28. The insider Polymeropoulos Mihael Hristos sold $1.14 million. Birznieks Gunther had sold 8,525 shares worth $159,605 on Wednesday, February 28.

Among 4 analysts covering Vanda (NASDAQ:VNDA), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Vanda had 4 analyst reports since February 13, 2018 according to SRatingsIntel. The firm has “Buy” rating given on Tuesday, February 13 by Jefferies. On Monday, March 5 the stock rating was maintained by Oppenheimer with “Buy”. The stock of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) has “Buy” rating given on Wednesday, February 28 by Seaport Global.

Bogle Investment Management Lp increased Taylor Morrison Home Cl A (NYSE:TMHC) stake by 250,641 shares to 320,516 valued at $7.46 million in 2018Q1. It also upped Dell Technologies Inc Com Cl V stake by 56,584 shares and now owns 171,003 shares. Celgene Corp (NASDAQ:CELG) was raised too.

More important recent Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) news were published by: which released: “The Daily Biotech Pulse: FDA Panel Backs Insmed, Eidos’ Maiden Earnings, Paratek Awaits Adcom Verdict” on August 08, 2018, also published article titled: “Benzinga’s Biotech Pulse: Pfizer’s Xeljanz Gets EU Nod, NewLink Losses Narrow, Neuralstem Commences Stroke …”, published: “Benzinga’s Daily Biotech Pulse: Novartis Licenses Skin Drug, 2 Stocks To Debut” on July 19, 2018. More interesting news about Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) was released by: and their article: “The Week Ahead In Biotech: Conferences, PDUFA Dates, Earnings And IPOs” with publication date: July 28, 2018.

Investors sentiment decreased to 0.96 in 2018 Q1. Its down 0.21, from 1.17 in 2017Q4. It is negative, as 13 investors sold VNDA shares while 43 reduced holdings. 23 funds opened positions while 31 raised stakes. 45.90 million shares or 15.40% more from 39.77 million shares in 2017Q4 were reported. Pnc Fin Services Gp has 226,168 shares. New York-based Bluemountain Capital Management Ltd Limited Liability Company has invested 0.03% in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA). Manufacturers Life Insur The has 0% invested in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA). Foundry Limited Liability Corp has invested 0.04% in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA). Legal General Gru Public Ltd Llc reported 8,065 shares. Alliancebernstein Limited Partnership invested in 0% or 109,763 shares. Us Commercial Bank De invested in 0% or 160 shares. Credit Suisse Ag stated it has 0% in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA). Gemmer Asset Limited Company stated it has 0% of its portfolio in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA). Bnp Paribas Arbitrage Sa reported 9,342 shares or 0% of all its holdings. J Goldman Company Limited Partnership owns 202,648 shares. California State Teachers Retirement Systems reported 0% stake. State Common Retirement Fund owns 53,370 shares. Susquehanna Gp Limited Liability Partnership invested in 0% or 18,755 shares. Voya Inv Mgmt Ltd Limited Liability Company accumulated 20,118 shares.

Analysts await Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) to report earnings on November, 6. They expect $-0.06 EPS, up 40.00% or $0.04 from last year’s $-0.1 per share. After $0.09 actual EPS reported by Vanda Pharmaceuticals Inc. for the previous quarter, Wall Street now forecasts -166.67% negative EPS growth.

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:

Recent Posts